LCP
SIOX

Lamond Capital Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Lamond Capital Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-86,620
Closed -$14.1M – 14
2015
Q2 		$14.1M Buy
+86,620
New +$14.7M 14.34% 3

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lamond Capital Partners's SIOX Position: Q3 2015 in Review

Lamond Capital Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2015, closing a stake of 86,620 shares — an estimated $14.1M sold.

Lamond Capital Partners first reported a position in SIOX in Q2 2015 and held it in 1 quarter. The position peaked at $14.1M in Q2 2015. 71 funds tracked by Wall St. Rank hold SIOX as of Q3 2015.

  • Lamond Capital Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 86,620 Sio Gene Therapies Inc. Common Stock shares in Q3 2015, an estimated $14.1M.
  • Lamond Capital Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Lamond Capital Partners's Sio Gene Therapies Inc. Common Stock position peaked at $14.1M in Q2 2015.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2015.

Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.